The pharmacotherapy of depressive illness in adolescents: An open-label comparison of fluoxetine with imipramine-treated historical controls

Journal of Clinical Psychiatry

Volumn 60, Issue 3, 1999, Pages 164-169

  Strober, Michael ^a,b   DeAntonio, Mark ^a   Schmidt Lackner, Susan ^a   Pataki, Caroly ^a   Freeman, Roberta ^a   Rigali, Joanne ^a   Rao, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; FOLLOW UP; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; RASH; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0032901377     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0303     Document Type: Article

References (39)

1. Shulman KI, Tohen M, Kutcher SP, eds. Mood Disorders Across the Lifespan. New York, NY: Wiley-Liss; 1996
2. Ryan N, Puig-Antich J, Cooper T, et al. Imipramine in adolescent major depression: plasma level and clinical response. Acta Psychiatr Scand 1986;73:275-288
3. Strober M, Freeman J, Rigali J. The pharmacotherapy of depressive illness in adolescence. Psychopharmacol Bull 1990;26:80-84
4. Geller B, Cooper TB, Graham DL, et al. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a fixed plasma level design. Psychopharmacol Bull 1990;26:85-90
5. Jensen PS, Ryan ND, Prien R. Psychopharmacology of child and adolescent major depression: present status and future directions. J Child Adolesc Psychopharmacol 1992;2:31-48
6. Conners CK. Methodology of antidepressant drug trials for treating depression in adolescents. J Child Adolesc Psychopharmacol 1992;2:11-22
7. Strober M. The pharmacotherapy of depressive illness in adolescents, III: diagnostic and conceptual issues in studies of tricyclic antidepressants. J Child Adolesc Psychopharmacol 1992;2:23-30
8. Boulos C, Kutcher S, Gardner D, et al. An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 1992;2:103-111
9. Ghaziuddin N, Naylor MW, King CA. Fluoxetine in tricyclic refractory depression in adolescents. Depression 1995;2:287-291
10. Jain U, Birmaher B, Garcia M, et al. Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse events. J Child Adolesc Psychopharmacol 1992;2:259-265
11. Simeon JG, Dinicola VF, Ferguson HB, et al. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:791-795
12. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 1997;54:1031-1037
13. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria for a Selected Group of Functional Disorders, 3rd ed. New York, NY: Biometric Research, New York State Psychiatric Institute; 1977
14. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978;35:837-844
15. Chambers WJ, Puig-Antich J, Hirsch M, et al. The assessment of affective disorders in children and adolescents by structured interview. Arch Gen Psychiatry 1985;42:696-702
16. Lukens E, Puig-Antich J, Behn J, et al. Reliability of the Psychosocial Schedule for School-Age Children. J Am Acad Child Adolesc Psychiatry 1983;22:29-39
17. Andreasen NC, Endicott J, Spitzer RL, et al. The family history method using diagnostic criteria. Arch Gen Psychiatry 1977;34:1229-1235
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
21. Pocock SJ. Clinical Trials. New York, NY: John Wiley & Sons; 1983
22. Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991;4:125-130
23. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 1992;41:203-214
24. Khan A, Brown WA. Who should receive antidepressants? Suggestions from placebo treatment. Psychopharmacol Bull 1991;27:271-274
25. Fairchild CJ, Rush, AJ, Vasavada N, et al. Which depressions respond to placebo? Psychiatry Res 1986;18:217-226
26. Quitkin FM, Stewart JM, McGrath PJ, et al. Phenylzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988;145:306-311
27. Black IB, Hendry IA, Iversen LL. Trans-synaptic regulation of growth and development of adrenergic neurons in a mouse sympathetic ganglion. Brain Res 1971;34:229-240
28. Goldman-Rakic P, Brown RM. Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Dev Brain Res 1982;4:339-349
29. Insel T, Battaglia G, Fairbanks D, et al. The ontogeny of brain receptors for corticotropin-releasing factor and the development of their functional association with adenylate cyclase. J Neurosci 1988;8:4151-4158
30. Smolen AJ, Beaston-Wimmer P, Wright LL. Neurotransmitter synthesis, storage, and turnover in neonatally deafferented sympathetic neurons. Dev Brain Res 1985;355:211-218
31. Thoenen H, Kettler R, Saner A. Time course of the development of enzymes involved in the synthesis of norepinephrine in the superior cervical ganglion of the rat from birth to adult life. Brain Res 1972;40:459-468
32. Murrin LC, Gibbens DL, Ferrer JR. Ontogeny of dopamine, serotonin, and spirodecanone receptors in rat forebrain: an autoradiographic study. Dev Brain Res 1985;355:91-109
33. Dahl R, Puig-Antich J, Ryan N, et al. Cortisol secretion in adolescents with major depression. Acta Psychiatr Scand 1989;80:18-26
34. Kutcher SP, Malkin D, Silverberg J, et al. Nocturnal cortisol, thyroid stimulating hormone, and growth hormone secreting properties in depressed adolescents, J Am Acad Child Adolesc Psychiatry 1991;30: 407-414
35. Kendall DA, Stancel GM, Enna SJ. Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science 1981;211: 1183-1185
36. Frank E, Karp JF, Rush AJ. Efficacy of treatments for depression. Psychopharmacol Bull 1993;29:457-476
37. Trivedi MH, Rush AJ. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994;11:33-43
38. McCracken JT, Poland RE. Reduced effect of antidepressant treatment on prolactin response to a serotonin agonist in prepubertal rats. J Child Adolesc Psychopharmacol 1995;5:115-120
39. Chamey DS, Heninger GR, Stemberg DE. Serotonin function and mechanisms of action of antidepressant treatment: effects of amitriptyline and desipramine. Arch Gen Psychiatry 1984;41:359-365